Bio Medica Laboratories IPO

Bio Medica Laboratories is involved in the manufacturing of pharmaceutical formulations through parenteral injections. This includes the manufacturing of generic drugs through injection in both single and multidose types for both humans and animals. The company operates purely on a B2B contractual manufacturing base. There are two main classifications under which the company offers its products. There are 58 liquid injectable formulations and 15 dry powder injectable formulations offered by the company.

The business earns income from two major sources, including sales of manufactured goods and the sales of trading goods. Third-party manufacturing is the main source of earning for the company. In FY25, third-party manufacturing earned the company ₹33.28 crore as against the total revenue of ₹38.20 crore, whereas in the case of products, the contribution was ₹24.43 crore for liquid injection and ₹13.42 crore for dry powder injection. The company also saw growth in veterinary medicines, where revenue rose steeply from ₹0.33 crore in FY24 to ₹4.42 crore in FY25.

There are two production plants which are situated in Indore, Madhya Pradesh. The top 10 customers have contributed 76.45% of revenue from the operation ended on November 30, 2025, where the largest customer contributed 30.56%. The top ten suppliers have contributed 77.9% of total purchases, while the largest supplier has contributed 58.1% of total purchases as on November 30, 2025.